Posts by: Alice Melão

News

High intensity interval training for 12 weeks can significantly improve neuronal activity and delay progression of Parkinson’s disease, correlating with an improvement in patients’ quality of life, according to ... Read more

October 8, 2019October 8, 2019

Impaired Immune Cells May Contribute to Parkinson’s Progression, Study Suggests

News

Reduced viability and impaired activity of monocytes — a subset of immune cells that circulate in the blood — may contribute to the progression of Parkinson’s disease. That discovery, ... Read more

October 7, 2019October 7, 2019

Nuplazid ‘Significantly’ Slows Relapses in Dementia-Related Psychosis, Phase 3 Trial Shows

News

Interim results from the ongoing Phase 3 HARMONY study show that treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in patients with dementia-related disorders, such as Parkinson’s and ... Read more

October 3, 2019October 3, 2019

Phase 2 Trial of SEP-363856, Potential Oral Treatment of Parkinson’s Psychosis, Enrolling in US

News

A Phase 2 clinical trial of SEP-363856, an oral treatment candidate for people with Parkinson’s psychosis, is now recruiting patients across the U.S. SEP-363856 is a candidate therapy being developed by ... Read more

September 30, 2019September 30, 2019

Daily Use of Cala Trio Device Effectively Eases Hand Tremors, Trial Reports

News

Using Cala Health’s non-invasive therapeutic device Cala Trio for 40 minutes twice daily effectively helped to reduce hand tremors within three months, results from a clinical study show. The ... Read more

September 25, 2019September 25, 2019

IRL752 May Help Manage Symptoms Unresponsive to L-Dopa, Phase 2 Data Suggests

News

The small molecule IRL752 may be a safe and effective treatment, which could potentially help manage symptoms known to be unresponsive to levodopa, for people with Parkinson’s disease dementia, results ... Read more

September 10, 2019September 10, 2019

Parkinson’s May Originate From Alpha-Synuclein Migrating From the Gut, Rat Study Shows

News

New experimental evidence collected from rats shows that alpha-synuclein — the protein that causes Parkinson’s disease — can travel from the intestines to other organs, such as the heart ... Read more

July 12, 2019July 12, 2019

Onstryv Now Available to Patients with Parkinson’s Disease in Canada

News

Patients in Canada with diagnosed Parkinson’s disease can now receive Onstryv (safinamide) to help manage their symptoms and their “off” episodes. This follows the approval of Onstryv by Health ... Read more

July 10, 2019August 27, 2019

Prevail’s Gene Therapy Candidate PR001 Granted FDA Fast Track Status

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Prevail Therapeutics’ lead gene therapy candidate, PR001, for the treatment of people with Parkinson’s disease associated with ... Read more

July 8, 2019July 8, 2019

Gene Therapy Used to Produce and Sustain Dopamine in Brains of Primate Model of Parkinson’s

News

Direct delivery of two dopamine-synthesizing enzymes to the midbrain, using a safe and inactive form of an adenovirus, was able to effectively ease signs of motor difficulties in a ... Read more

Posts by: Alice Melão

Alice Melão

High Intensity Interval Training May Benefit Patients with Parkinson’s, Pilot Study Shows

Impaired Immune Cells May Contribute to Parkinson’s Progression, Study Suggests

Phase 2 Trial of SEP-363856, Potential Oral Treatment of Parkinson’s Psychosis, Enrolling in US

Daily Use of Cala Trio Device Effectively Eases Hand Tremors, Trial Reports

IRL752 May Help Manage Symptoms Unresponsive to L-Dopa, Phase 2 Data Suggests

Parkinson’s May Originate From Alpha-Synuclein Migrating From the Gut, Rat Study Shows

Onstryv Now Available to Patients with Parkinson’s Disease in Canada

Prevail’s Gene Therapy Candidate PR001 Granted FDA Fast Track Status

Gene Therapy Used to Produce and Sustain Dopamine in Brains of Primate Model of Parkinson’s

Pin It on Pinterest